Nuclear Medicine Software Market To Reach USD 1,803.9 Million By 2032 Amid Rising Incidence Of Chronic Diseases
Event | Description and Impact |
Surge in AI/ML-Based Medical Device Approvals (2024–2025) |
|
Pharmaceutical Investments in Radiopharmaceuticals (2024–2025) |
|
Cybersecurity Regulations and Healthcare Data Protection |
|
Competitor Insights
Key companies in the nuclear medicine software market report:
- GE HealthCare Siemens Healthineers Philips Healthcare Canon Medical Systems Corporation Hermes Medical Solutions AB Bracco Imaging S.p.A. Segami Corporation MIM Software Inc. INVIA Medical Imaging Solutions Mirada Medical Ltd. PMOD Technologies LLC Nuclear Diagnostics AB Sofie Biosciences Inc. Xeleris Mediso Medical Imaging Systems
Key Developments
In June 2025, GE HealthCare enhanced its precision care by launching the new MIM Encore software. This novel software is designed to solve healthcare challenges by boosting efficiency, cutting down manual work, and improving communication.
In May 2025, Hermes Medical Solutions released new updates to its Hermia software suite. These novel innovations are designed to advance precision and efficiency in nuclear medicine imaging and dosimetry.
In December 2024, Royal Philips unveiled its newest AI-powered imaging tools for diagnosis and treatment at the RSNA 2024 conference. These tools aim to improve precision imaging by making workflows faster, simpler, and more efficient. They are designed to help radiologists overcome different challenges.
Market Segmentation
- Type Insights (Revenue, USD Mn, 2020 - 2032)
- Patient Data Management Software Imaging and Visualization Software Analysis and Quantification Software Clinical Decision Support Software Dosimetry Software Workflow and Scheduling Software Treatment Planning Software Others (Artificial Intelligence (AI) and Analytics Software, etc.)
- Positron Emission Tomography (PET) Single Photon Emission Computed Tomography (SPECT) Hybrid Imaging Software (PET/CT, SPECT/CT, PET/MRI) Others (Planar Scintigraphy, hybrid systems)
- Oncology Cardiology Neurology Endocrinology Gastroenterology Others (Orthopedics, Infectious disease imaging, etc.)
- On-Premise Cloud-Based
- Standalone Software Integrated Software Solutions
- Subscription-based Pricing Perpetual License Pricing Usage-based Pricing (pay-per-use) Freemium or Trial-based Pricing Customized or Enterprise Pricing
- Hospitals and Clinics Diagnostic Imaging Centers Academic and Research Institutions Pharmaceutical and Biotechnology Companies
- North America
- U.S. Canada
- Brazil Argentina Mexico Rest of Latin America
- Germany U.K. Spain France Italy Russia Rest of Europe
- China India Japan Australia South Korea ASEAN Rest of Asia Pacific
- GCC Countries Israel Rest of Middle East
- South Africa North Africa Central Africa
Read Report:
Nuclear Imaging Equipment Market Size, Share, Trends & Opportunities for 2025-2032
Radiopharmaceuticals in Nuclear Medicine Market Size, Share & Trends Analysis Report (2025-2032)
Nuclear Medicine Market Size, Share, Trends & Opportunities for 2025-2032


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Stonehaven Circle Marks 13Th Anniversary With Hadrian Colwyn Leading Calvio Ailegacyx Innovation
- Bitmex Launches Alpha Showdown Trading Competition Featuring 3 BTC Prize Pool And Additional Rewards
- Thrivestate Launches“Fly Before You Buy” Program, Enabling International Buyers To Explore Dubai Before Committing
- 1Inch Becomes First Swap Provider Relaunched On OKX Wallet
- Ozak AI Partners With Pyth Network To Deliver Real-Time Market Data Across 100+ Blockchains
- Xfunded Expands In Dubai, Strengthening Collaborations With Trading Influencers Across Europe
Comments
No comment